These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 11150026

  • 1. Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization.
    Casonato A, Pontara E, Sartorello F, Bertomoro A, Durante C, Girolami A.
    J Lab Clin Med; 2001 Jan; 137(1):70-6. PubMed ID: 11150026
    [Abstract] [Full Text] [Related]

  • 2. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ.
    Acta Haematol; 2009 Jan; 121(2-3):71-84. PubMed ID: 19506352
    [Abstract] [Full Text] [Related]

  • 3. A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function.
    Casonato A, Cattini MG, Soldera C, Marcato S, Sartorello F, Pontara E, Pagnan A.
    J Lab Clin Med; 2004 Nov; 144(5):254-9. PubMed ID: 15570243
    [Abstract] [Full Text] [Related]

  • 4. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ, Gadisseur A, Vangenegten I, Schroyens W, Berneman Z.
    Acta Haematol; 2009 Nov; 121(2-3):119-27. PubMed ID: 19506358
    [Abstract] [Full Text] [Related]

  • 5. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A, van der Planken M, Schroyens W, Berneman Z, Michiels JJ.
    Acta Haematol; 2009 Nov; 121(2-3):145-53. PubMed ID: 19506361
    [Abstract] [Full Text] [Related]

  • 6. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease.
    Casonato A, Pontara E, Sartorello F, Cattini MG, Sartori MT, Padrini R, Girolami A.
    Blood; 2002 Jan 01; 99(1):180-4. PubMed ID: 11756169
    [Abstract] [Full Text] [Related]

  • 7. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A, Berneman Z, Schroyens W, Michiels JJ.
    Acta Haematol; 2009 Jan 01; 121(2-3):128-38. PubMed ID: 19506359
    [Abstract] [Full Text] [Related]

  • 8. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ, van de Velde A, van Vliet HH, van der Planken M, Schroyens W, Berneman Z.
    Semin Thromb Hemost; 2002 Apr 01; 28(2):111-32. PubMed ID: 11992235
    [Abstract] [Full Text] [Related]

  • 9. A probable double heterozygous type II von Willebrand's disease with increased ristocetin induced platelet aggregation.
    Kinoshita S, Yoshioka K, Kasahara M, Takamiya O.
    Am J Hematol; 1992 Jul 01; 40(3):192-8. PubMed ID: 1609773
    [Abstract] [Full Text] [Related]

  • 10. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
    Lanke E, Kristoffersson AC, Isaksson C, Holmberg L, Lethagen S.
    Eur J Haematol; 2008 Nov 01; 81(5):384-90. PubMed ID: 18637125
    [Abstract] [Full Text] [Related]

  • 11. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA, Mancuso DJ, Evan Sadler J, Ponder JW, Jozwiak MA, Christopherson PA, Cox Gill J, Paul Scott J, Montgomery RR.
    Blood; 1998 Mar 01; 91(5):1572-81. PubMed ID: 9473222
    [Abstract] [Full Text] [Related]

  • 12. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A, Pontara E, Dannhäuser D, Bertomoro A, Sartori MT, Girolami A.
    Haematologia (Budap); 1994 Mar 01; 26(2):97-109. PubMed ID: 7890268
    [Abstract] [Full Text] [Related]

  • 13. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers.
    Weiss HJ, Sussman II.
    Blood; 1986 Jul 01; 68(1):149-56. PubMed ID: 3487353
    [Abstract] [Full Text] [Related]

  • 14. Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity?
    Casonato A, Pontara E, Bertomoro A, Sartorello F, Cattini MG, Girolami A.
    Br J Haematol; 2001 Mar 01; 112(3):578-83. PubMed ID: 11260057
    [Abstract] [Full Text] [Related]

  • 15. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A, Sartorello F, Pontara E, Gallinaro L, Bertomoro A, Grazia Cattini M, Daidone V, Szukowska M, Pagnan A.
    Thromb Haemost; 2007 Dec 01; 98(6):1182-7. PubMed ID: 18064311
    [Abstract] [Full Text] [Related]

  • 16. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan 01; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 17. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ, van Vliet HH.
    Acta Haematol; 2009 Jan 01; 121(2-3):154-66. PubMed ID: 19506362
    [Abstract] [Full Text] [Related]

  • 18. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
    Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van Vliet HH.
    Acta Haematol; 2009 Jan 01; 121(2-3):85-97. PubMed ID: 19506353
    [Abstract] [Full Text] [Related]

  • 19. Molecular genetics of type 2 von Willebrand disease.
    Fressinaud E, Mazurier C, Meyer D.
    Int J Hematol; 2002 Jan 01; 75(1):9-18. PubMed ID: 11843298
    [Abstract] [Full Text] [Related]

  • 20. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Semin Thromb Hemost; 2005 Nov 01; 31(5):577-601. PubMed ID: 16276467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.